This article was originally published in The Gray Sheet
Anika Therapeutics: Premarket approval application for the firm's Orthovisc intra-articular injectable hyaluronic acid treatment for osteoarthritis of the knee has been accepted for filing by FDA following submission in December, the firm states ("The Gray Sheet" Jan. 5, In Brief). The notification states that FDA does not plan to refer the PMA for advisory panel review, Anika reports...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.